Indications
Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
Composition
- Active substance
- daclizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zinbryta
- Active substance
- daclizumab
- ATC code
- L04AC01
- Therapeutic area
- Multiple Sclerosis
- Marketing authorisation holder
- Biogen Idec Ltd
- Status
- Withdrawn
- EU authorisation
- 1 Jul 2016
- Withdrawn